The purpose of this study is to explore the efficacy of Aggrenox in patients with SARS-CoV-2 infection with symptoms consistent with COVID-19. An anticipated total of 132 participants will be randomly divided almost equally into 2 groups: one group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally along with the standard of care and the other group with receive the standard of care only but no Dipyridamole ER 200mg/ Aspirin 25mg. Participants will be screened, enrolled, receive treatment, and followed for 28 days. The clinical and laboratory outcomes of all the participants enrolled in the study will be evaluated at the end of the study to explore if there is any difference in the outcomes between 2 groups.

Start Date21 Oct 2020

Sponsor / Collaborator

Rutgers State University of New Jersey

[+1]

NCT04360720 / RecruitingPhase 3IIT

PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System in Brazil

Phase-3, randomized, multicenter, parallel-group study with blind evaluation of endpoints and intention-to-treat analysis.
The general purpose of the study is evaluate the non-inferiority hypothesis for ischemic events and the superiority hypothesis for bleeding events resulting from platelet P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary intervention in the context of the Unified Health System in Brazil.

Start Date15 Oct 2020

Sponsor / Collaborator

Hospital Israelita Albert Einstein

NCT01781611 / TerminatedNot ApplicableIIT

Dipyridamole Assessment for Flare Reduction in SLE

Dipyridamole, a medication extensively used in combination with aspirin for stroke prevention, is a promising new treatment for lupus. Dipyridamole has been shown to inhibit certain lymphocyte populations that are over-reactive in lupus and to delay the emergence of lupus-related pathology in mice with lupus. The investigators are interested in investigating the efficacy of dipyridamole in preventing flares in patients with lupus and its impact on biomarkers of disease activity.

Start Date01 Feb 2013

Sponsor / Collaborator

Oklahoma Medical Research Foundation

100 Clinical Results associated with Aspirin/Dipyridamole

100 Translational Medicine associated with Aspirin/Dipyridamole

100 Patents (Medical) associated with Aspirin/Dipyridamole

Literatures (Medical) associated with Aspirin/Dipyridamole

01 Aug 2024·Pain Physician

Updated Assessment of Practice Patterns of Perioperative Management of Antiplatelet and Anticoagulant Therapy in Interventional Pain Management.

Article

Author: Manchikanti, Laxmaiah ; Hirsch, Joshua A ; Soin, Amol ; Pampati, Vidyasagar ; Sanapati, Mahendra R

BACKGROUND:

The role of antiplatelet/anticoagulant therapy is well known for its primary and secondary prevention of sequela from cardiovascular disease by decreasing the incidence of acute cerebral, cardiovascular, peripheral vascular, and other thrombo-embolicevents. The overwhelming data show that the risk of thrombotic events is significantly higher than that of bleeding during surgery after antiplatelet drug discontinuation. It has been assumed that discontinuing antiplatelet therapy prior to performing interventional pain management techniques is a common practice, even though doing so may potentially increase the risk of acute cerebral and cardiovascular events. A survey of practice patterns was conducted in 2012, since then the risks associated with thromboembolic events and bleeding, has not been systematically evaluated.

OBJECTIVE:

To conduct an updated assessment of the perioperative antiplatelet and anticoagulant practice patterns of U.S. interventional pain management physicians and compare this with data collected in 2012 with 2021 data regarding practice patterns of continuing or discontinuing anticoagulant therapy. STUDY DESIGNn: Postal survey of interventional pain management physicians.

STUDY SETTING:

Interventional pain management practices in the United States.

METHODS:

The survey was conducted based on online responses of the members of the American Society of Interventional Pain Physicians (ASIPP) in 2021. The survey was designed similar to the 2012 survey to assess updated practice patterns.

RESULTS:

The questionnaire was sent out to 1,700 members in October 2021. Out of these, 185 members completed the survey, while 105 were returned due to invalid addresses. The results showed that 23% changed their practice patterns during the previous year. The results also showed that all physicians discontinued warfarin therapy with the majority of physicians accepting an INR of 1.5 as a safe level. Low dose aspirin (81 mg) was discontinued for 3 to 7 days for low-risk procedures by 8% of the physicians, 34% of the physicians for moderate or intermediate risk procedures, whereas they were discontinued by 76% of the physicians for high-risk procedures. High dose aspirin (325 mg) was discontinued at a higher rate. Antiplatelet agents, including dipyridamole, cilostazol, and Aggrenox (aspirin, extended-release dipyridamole) were discontinued from 3 to 5 days by 18%-23% of the physicians for low-risk procedures, approximately 60% of the physicians for moderate or intermediate-risk procedures, and over 90% of the physicians for high-risk procedures. Platelet aggregation inhibitors clopidogrel, prasugrel, ticlopidine, and ticagrelor were discontinued for 3 to 5 days by approximately 26% to 41% for low-risk procedures, almost 90% for moderate or intermediate-risk procedures, and over 97% for high-risk procedures. Thrombin inhibitor dabigatran was discontinued by 33% of the physicians for low-risk procedures, 92% for moderate or intermediate-risk procedures, and 99% for high-risk procedures. Anti-Xa agents, apixaban, rivaroxaban, and Edoxaban were discontinued in over 25% of the physicians for low-risk procedures, approximately 90% for moderate or intermediate-risk procedures, and 99% for high-risk procedures.

LIMITATIONS:

This study was limited by its being an online survey of the membership of one organization in one country, that there was only a 11.6% response rate, and the sample size is relatively small. Underreporting in surveys is common. Further, the incidence of thromboembolic events or epidural hematomas was not assessed.

CONCLUSION:

The results in the 2021 survey illustrate a continued pattern of discontinuing antiplatelet and anticoagulant therapy in the perioperative period. The majority of discontinuation patterns appear to fall within guidelines.

11 Jan 2019·Pain physicianQ3 · MEDICINE

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines

Q3 · MEDICINE

Review

Author: Amol Soin ; Cyrus Bakhit ; Ramarao Pasupuleti ; Sudhir Diwan ; Jay S. Grider ; Michael E. Harned ; Muhammad Anwar ; Ramsin M. Benyamin ; Kenneth D. Candido ; Matthew R. Eng ; Elyse M. Cornett ; Mahendra Sanapati ; Matthew B. Novitch ; Hari Prabhakar ; Nebojsa Nick Knezevic ; Mark R. Jones ; Imran N. Mungrue ; Richard E. Latchaw ; Erik M. Helander ; Joshua A. Hirsch ; Timothy R. Deer ; Alan D. Kaye ; Sheri L. Albers ; John R. Swicegood ; Douglas Beall ; Ricardo Vallejo ; Salahadin Abdi ; Thomas T. Simopoulos ; Laxmaiah Manchikanti ; Richard D. Urman ; Sairam Atluri

Background: Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in interventional pain are medicated using anticoagulant or antithrombotic drugs to mitigate thrombosis risk. Since these drugs target the clotting system, bleeding risk is a consideration accompanying interventional procedures. Importantly, discontinuation of anticoagulant or antithrombotic drugs exposes underlying thrombosis risk, which can lead to significant morbidity and mortality especially in those with coronary artery or cerebrovascular disease. This review summarizes the literature and provides guidelines based on best evidence for patients receiving anti-clotting therapy during interventional pain procedures. Study Design: Best evidence synthesis. Objective: To provide a current and concise appraisal of the literature regarding an assessment of the bleeding risk during interventional techniques for patients taking anticoagulant and/or antithrombotic medications. Methods: A review of the available literature published on bleeding risk during interventional pain procedures, practice patterns and perioperative management of anticoagulant and antithrombotic therapy was conducted. Data sources included relevant literature identified through searches of EMBASE and PubMed from 1966 through August 2018 and manual searches of the bibliographies of known primary and review articles. Results: 1. There is good evidence for risk stratification by categorizing multiple interventional techniques into low-risk, moderate-risk, and high-risk. Also, their risk should be upgraded based on other risk factors. 2. There is good evidence for the risk of thromboembolic events in patients who interrupt antithrombotic therapy. 3. There is good evidence supporting discontinuation of low dose aspirin for high risk and moderate risk procedures for at least 3 days, and there is moderate evidence that these may be continued for low risk or some intermediate risk procedures.4. There is good evidence that discontinuation of anticoagulant therapy with warfarin, heparin, dabigatran (Pradaxa®), argatroban (Acova®), bivalirudin (Angiomax®), lepirudin (Refludan®), desirudin (Iprivask®), hirudin, apixaban (Eliquis®), rivaroxaban (Xarelto®), edoxaban (Savaysa®, Lixiana®), Betrixaban(Bevyxxa®), fondaparinux (Arixtra®) prior to interventional techniques with individual consideration of pharmacokinetics and pharmacodynamics of the drugs and individual risk factors increases safety. 5. There is good evidence that diagnosis of epidural hematoma is based on severe pain at the site of the injection, rapid neurological deterioration, and MRI with surgical decompression with progressive neurological dysfunction to avoid neurological sequelae. 6. There is good evidence that if thromboembolic risk is high, low molecular weight heparin bridge therapy can be instituted during cessation of the anticoagulant, and the low molecular weight heparin can be discontinued 24 hours before the pain procedure. 7. There is fair evidence that the risk of thromboembolic events is higher than that of epidural hematoma formation with the interruption of antiplatelet therapy preceding interventional techniques, though both risks are significant. 8. There is fair evidence that multiple variables including anatomic pathology with spinal stenosis and ankylosing spondylitis; high risk procedures and moderate risk procedures combined with anatomic risk factors; bleeding observed during the procedure, and multiple attempts during the procedures increase the risk for bleeding complications and epidural hematoma. 9. There is fair evidence that discontinuation of phosphodiesterase inhibitors is optional (dipyridamole [Persantine], cilostazol [Pletal]. However, there is also fair evidence to discontinue Aggrenox [dipyridamole plus aspirin]) 3 days prior to undergoing interventional techniques of moderate and high risk. 10. There is fair evidence to make shared decision making between the patient and the treating physicians with the treating physician and to consider all the appropriate risks associated with continuation or discontinuation of antithrombotic or anticoagulant therapy. 11. There is fair evidence that if thromboembolic risk is high antithrombotic therapy may be resumed 12 hours after the interventional procedure is performed. 12. There is limited evidence that discontinuation of antiplatelet therapy (clopidogrel [Plavix®], ticlopidine [Ticlid®], Ticagrelor [Brilinta®] and prasugrel [Effient®]) avoids complications of significant bleeding and epidural hematomas. 13. There is very limited evidence supporting the continuation or discontinuation of most NSAIDs, excluding aspirin, for 1 to 2 days and some 4 to 10 days, since these are utilized for pain management without cardiac or cerebral protective effect. Limitations: The continued paucity of the literature with discordant recommendations. Conclusion: Based on the survey of current literature, and published clinical guidelines, recommendations for patients presenting with ongoing antithrombotic therapy prior to interventional techniques are variable, and are based on comprehensive analysis of each patient and the risk-benefit analysis of intervention. Key words: Perioperative bleeding, bleeding risk, practice patterns, anticoagulant therapy, antithrombotic therapy, interventional techniques, safety precautions, pain

01 Jan 2019·Journal of thrombosis and haemostasis : JTHQ2 · MEDICINE

Preventing arteriovenous shunt failure in hemodialysis patients: a population‐based cohort study

Q2 · MEDICINE

Article

Author: Yang, C W ; Wu, H H ; Chang, T-Y ; Liu, S H ; Lee, C C ; Kuo, C F ; Tian, Y C ; Hsieh, M Y ; Weng, C H ; Fan, P Y ; Tu, K H ; Li, I-J

Essentials Uncertainty remains about antiplatelets for vascular access patency in hemodialysis patients. 95 971 people under hemodialysis were followed in a claims database in Taiwan. Aspirin reduced vascular access failure rate and did not increase major bleeding rate. Clopidogrel, Aggrenox, and warfarin might increase major bleeding rate. SUMMARY: Background Dialysis adequacy is a major determinant of survival for patients with end-stage renal disease. Good vascular access is essential to achieve adequate dialysis. Objectives This study evaluated the impacts of different drugs on the vascular access failure rate of an arteriovenous fistula or an arteriovenous graft and the rate of major bleeding in hemodialysis patients. Patients and methods We studied patients with end-stage renal disease registered in the Taiwan National Health Insurance program from 1 January 1997 to 31 December 2012. A total of 95 971 patients were enrolled in our study. Vascular access dysfunction was defined as the need for thrombectomy or percutaneous angioplasty. Major bleeding was defined as emergency department visits or hospitalization with a primary diagnosis of gastrointestinal bleeding or intracerebral hemorrhage. The adjusted odds ratios between person-quarters with or without antiplatelet or oral anticoagulant use were calculated using a generalized estimating equation. Results The odds ratio of vascular access failure was 0.21 (0.11-0.39) for aspirin, 0.76 (0.74-0.79) for clopidogrel, 0.67 (0.59-0.77) for dipyridamole, 0.67 (0.53-0.86) for Aggrenox and 0.96 (0.90-1.03) for warfarin. The highest odds ratio for intracerebral hemorrhage was 5.33 (1.25-22.72) in younger patients using Aggrenox. The highest odds ratio for gastrointestinal bleeding was 1.34 (1.10-1.64) for clopidogrel. Conclusion Antiplatelet agents, but not warfarin, might reduce the vascular access thrombosis rate. The gastrointestinal bleeding rate was increased in the group using clopidogrel. Aggrenox should be used with caution in young individuals because it might increase the rate of intracerebral hemorrhage.

News (Medical) associated with Aspirin/Dipyridamole

23 Sep 2022

·www.prnewswire.com

Progesterone Market Size to Grow by USD 1.23 Billion, Rise in Research and Development of Progesterone Drugs -Technavio

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- One of the key trends in the progesterone market is the rise in research and development of progesterone drugs. Various players are expanding their research to develop new formulations of the existing female infertility drugs due to the significant unmet demand. For instance, MVT-602 targets the kisspeptin system to stimulate reproductive hormones. It can effectively treat many reproductive disorders such as PCOS and hypothalamic amenorrhea (HA). Continue Reading Technavio has announced its latest market research report titled Global Progesterone Market 2022-2026 The progesterone market size is expected to grow by USD 1.23 billion. In addition, the growth momentum of the market will accelerate at a CAGR of 12.96% during the forecast period, according to Technavio. Get a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample report is available in PDF format The increasing prevalence of breast cancer is driving the progesterone market growth. However, factors such as stringent regulations may challenge the market growth during the forecast period. Progesterone Market: Type Landscape By type, the market has been segmented into synthetic progesterone and natural progesterone. The synthetic progesterone segment will be the largest contributor to market growth during the forecast period. Synthetic progesterone drugs help regulate the monthly menstrual cycle. Therefore, the advantages of synthetic progesterone will accelerate the market growth during the forecast period. Progesterone Market: Geographic Landscape By geography, the market has been segmented into North America, Europe, Asia, and Rest of World (ROW). North America is going to have lucrative growth during the forecast period. About 43% of the market's overall growth is expected to originate from North America. The US and Canada are the key countries for the progesterone market in North America. The growth of the region is attributed to factors such as the rising prevalence of kidney, breast, or uterine cancer types and the rising population of menopausal women. Some Key Companies and their Offerings AbbVie Inc., Alkem Laboratories Ltd., Aquatic Group, Bionpharma Inc., Blubell Pharma Group, Cadila Pharmaceuticals Ltd., Caesar and Loretz GmbH, Cipla Ltd., Dr. Reddys Laboratories Ltd., Estrellas Life Sciences Pvt. Ltd., Fagron NV, Glenmark Pharmaceuticals Ltd, Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Kiama Lifesciences, Lupin Ltd., Organon and Co., PROCAPS S.A, Teva Pharmaceutical Industries Ltd., Virtus Pharmaceuticals LLC, among others, are the main players in the market. The key offerings of some of these vendors are listed below: Alkem Laboratories Ltd. - The company offers ULTIGEST SR 200MG TAB as medication for a hormone prescribed for replacement therapy in women who have passed menopause. Aquatic Group - The company offers injection I.P Luteum Depot as progesterone drugs. Bionpharma Inc. - The company manufactures progesterone drugs. Blubell Pharma Group - The company offers BELGEST 500 and BELGEST N under the injection section as progesterone. Cadila Pharmaceuticals Ltd. - The company offers ALGEST SR 400MG tab as progesterone drugs, which are made using milk-making glands to help in the menstrual cycle. This report provides a full list of key vendors, their strategies, and the latest developments. Request a FREE PDF Sample Now What our Reports Offer Market share assessments for the regional-level and country-level segments Strategic recommendations for the new entrants Covers market data for 2021, 2022, until 2026 Market trends (opportunities, drivers, threats, challenges, investment opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping mapping the key common trends Company profiling with financials, detailed strategies, and recent developments Supply chain trends mapping the latest technological advancements Related Reports Women's Health Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026: The women's health therapeutics market share is expected to increase by USD 30.35 billion from 2021 to 2026. Stem Cell Umbilical Cord Blood (UCB) Market by End-user and Geography - Forecast and Analysis 2022-2026: The stem cell umbilical cord blood (UCB) market share is expected to increase by USD 1.47 bn from 2021 to 2026. Browse Health Care Market Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 Synthetic progesterone - Market size and forecast 2021-2026 Exhibit 28: Chart on Synthetic progesterone - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Synthetic progesterone - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Synthetic progesterone - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Synthetic progesterone - Year-over-year growth 2021-2026 (%) 5.4 Natural progesterone - Market size and forecast 2021-2026 Exhibit 32: Chart on Natural progesterone - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Natural progesterone - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Natural progesterone - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Natural progesterone - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Type Exhibit 36: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 UK - Market size and forecast 2021-2026 Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.10 Canada - Market size and forecast 2021-2026 Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.11 France - Market size and forecast 2021-2026 Exhibit 74: Chart on France - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on France - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on France - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on France - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 Alkem Laboratories Ltd. Exhibit 85: Alkem Laboratories Ltd. - Overview Exhibit 86: Alkem Laboratories Ltd. - Business segments Exhibit 87: Alkem Laboratories Ltd. - Key news Exhibit 88: Alkem Laboratories Ltd. - Key offerings Exhibit 89: Alkem Laboratories Ltd. - Segment focus 10.4 Aquatic Group Exhibit 90: Aquatic Group - Overview Exhibit 91: Aquatic Group - Product / Service Exhibit 92: Aquatic Group - Key offerings 10.5 Bionpharma Inc. Exhibit 93: Bionpharma Inc. - Overview Exhibit 94: Bionpharma Inc. - Product / Service Exhibit 95: Bionpharma Inc. - Key offerings 10.6 Blubell Pharma Group Exhibit 96: Blubell Pharma Group - Overview Exhibit 97: Blubell Pharma Group - Product / Service Exhibit 98: Blubell Pharma Group - Key offerings 10.7 Cadila Pharmaceuticals Ltd. Exhibit 99: Cadila Pharmaceuticals Ltd. - Overview Exhibit 100: Cadila Pharmaceuticals Ltd. - Business segments Exhibit 101: Cadila Pharmaceuticals Ltd. - Key offerings Exhibit 102: Cadila Pharmaceuticals Ltd. - Segment focus 10.8 Estrellas Life Sciences Pvt. Ltd. Exhibit 103: Estrellas Life Sciences Pvt. Ltd. - Overview Exhibit 104: Estrellas Life Sciences Pvt. Ltd. - Product / Service Exhibit 105: Estrellas Life Sciences Pvt. Ltd. - Key offerings 10.9 Intas Pharmaceuticals Ltd. Exhibit 106: Intas Pharmaceuticals Ltd. - Overview Exhibit 107: Intas Pharmaceuticals Ltd. - Product / Service Exhibit 108: Intas Pharmaceuticals Ltd. - Key offerings 10.10 PROCAPS S.A Exhibit 109: PROCAPS S.A - Overview Exhibit 110: PROCAPS S.A - Product / Service Exhibit 111: PROCAPS S.A - Key offerings 10.11 Teva Pharmaceutical Industries Ltd. Exhibit 112: Teva Pharmaceutical Industries Ltd. - Overview Exhibit 113: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key news Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 116: Teva Pharmaceutical Industries Ltd. - Segment focus 10.12 Virtus Pharmaceuticals LLC Exhibit 117: Virtus Pharmaceuticals LLC - Overview Exhibit 118: Virtus Pharmaceuticals LLC - Product / Service Exhibit 119: Virtus Pharmaceuticals LLC - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 120: Inclusions checklist Exhibit 121: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 122: Currency conversion rates for US$ 11.4 Research methodology Exhibit 123: Research methodology Exhibit 124: Validation techniques employed for market sizing Exhibit 125: Information sources 11.5 List of abbreviations Exhibit 126: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

21 Oct 2010

·www.pharmatimes.com

NICE launches database for referral advice

The National Institute for Health and Clinical Excellence has launched a database pulling together its recommendations on referring patients from primary to secondary care to improve outcomes and cut costs. The database will provide GPs with a one-stop-shop of guidance highlighting when patients could benefit from secondary care or specialist services, which, aside from securing better value for money and clinical outcomes, should help to improve the patient experience and reduce local and regional inequalities in care, the Institute said. Inappropriate referral to secondary care represents a significant and unnecessary cost to the NHS, and the database is one of a number of initiatives designed to help the health service deliver the QIPP (Quality, Improvement, Productivity and Prevention) agenda during a time of financial constraint. Professor Peter Littlejohns, NICE Clinical and Public Health Director said the new ‘referral advice’ recommendations database “is a valuable resource for those providing and commissioning care on when patients should be referred on from primary care”, which should help to ensure that patients receive treatment that is proven to be both clinically and cost effective. Final guidance for clopidogrel/dipyridamol Meanwhile, the cost watchdog has endorsed the wider use of clopidogrel as well as Boehringer Ingelheim’s modified-release dipyridamol for the prevention of occlusive vascular events. The Institute has OK’d funding for the wider use of clopidogrel (using the least costly preparation) in National Health Service patients who have had a stroke or who have peripheral arterial disease, and those who have cardiovascular disease in more than one area, to help prevent a subsequent heart attack or stroke. However, the drug is only recommended for patients who have had a heart attack if they are unable to take aspirin. A combination of modified-release dipyridamole - sold as Persantin Retard and Asasantin Retard by Boehringer - and aspirin is backed as an option for patients who have had a transient ischaemic attack, but should only be used when patients have had an ischaemic stroke where clopidogrel is contraindicated or not tolerated. The drug can also be used alone as an option following ischaemic stroke where aspirin and clopidogrel cannot be taken, the Institute said. Professor Peter Littlejohns, Clinical and Public Health Director at NICE, noted that heart attacks and strokes are some of the biggest killers and causes of disability the country, and that the new guidelines have “the potential to have a significant impact on the treatment of many thousands of patients in England and Wales”.

100 Deals associated with Aspirin/Dipyridamole

External Link

KEGG	Wiki	ATC	Drug Bank
-	Aspirin/Dipyridamole	A01AD05 B01AC06 N02BA01	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Stroke	CA	Boehringer Ingelheim GmbH	17 Apr 2000
Ischemic Attack, Transient	US	Boehringer Ingelheim Pharmaceuticals, Inc.	22 Nov 1999
Ischemic stroke	US	Boehringer Ingelheim Pharmaceuticals, Inc.	22 Nov 1999
Cerebral Infarction	CN	Dezhou Bocheng Pharmacy Co. Ltd.	01 Jan 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post Acute COVID 19 Syndrome	Phase 3	US	Boehringer Ingelheim GmbH	21 Oct 2020
Brain Infarction	Phase 3	JP	Boehringer Ingelheim GmbH	01 Apr 2006
Headache	Phase 3	TW	Boehringer Ingelheim GmbH	01 Sep 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01781611 (DARE, CTgov)	Not Applicable	Systemic Lupus Erythematosus	18	extended release dipyridamole 200mg/aspirin 25mg (Extended Release Dipyridamole/Aspirin)	zfdsmuvdex(bfnjymojuz) = ntfeuqsvil nwctrqbqqd (sdhslmhcwm, irlrsrekcp - nanphawags) View more	-	25 Nov 2020
				81mg aspirin (Aspirin)	zfdsmuvdex(bfnjymojuz) = fjbqukmbht nwctrqbqqd (sdhslmhcwm, mqjovxgfxi - nerotahibk) View more
ASN2018	Not Applicable	Dialysis Access Failure	-	Aspirin	fsjnqgdsol(vfkrcgszmn) = mklwanqypl oahmqumnmy (pmoonxxqsm, 0.10 - 0.28) View more	Positive	23 Oct 2018
				Clopidogrel	fsjnqgdsol(vfkrcgszmn) = jggoneiabw oahmqumnmy (pmoonxxqsm, 0.67 - 0.71) View more
NCT00738894 (REDUCE, CTgov)	Not Applicable	Foramen Ovale, Patent \| Stroke \| Ischemic Attack, Transient	664	Septal Occluder Device+Plavix+Aggrenox+Clopidogrel+Dipyridamole+Aspirin (Device Closure)	virrvjvdpi(isxnsmnevv) = kqukxwuqta slpcvnhhad (tawxdqtdfa, czbwygsvef - kioboqyami) View more	-	09 Aug 2018
				Plavix+Aggrenox+Clopidogrel+Dipyridamole+Aspirin (Medical Management)	virrvjvdpi(isxnsmnevv) = bysgyhwjii slpcvnhhad (tawxdqtdfa, tufnrxienb - ythnvbfhug) View more
NCT00906035 (CTgov)	Not Applicable	Peripheral Arterial Disease	25	Aspirin 25mg bid: (Dipyridamole 200mg and Aspirin 25mg Bid)	gvmdrdnhmk(jzhmlqhtrz) = pnbmeatems gizsvvagdo (tugucstfhe, smnimxhigc - ziyebkmiwb) View more	-	05 Sep 2017
				Dipyridamole 200 mg bid (Dipyridamole 200 mg Bid)	gvmdrdnhmk(jzhmlqhtrz) = ilsihfqgrn gizsvvagdo (tugucstfhe, rarpjbkffr - tusnchxibi) View more
NCT00311402 (JASAP, CTgov)	Phase 3	Brain Infarction	1,295	Aggrenox capsule (Aggrenox Capsule)	iarasvdpaj(wkosvzjowt) = kjklkypefx ebxifilwfi (ghhbvcyhyr, ypdwufmuyk - dubdxrrewa) View more	-	11 Mar 2010
				Acetylsalicylic Acid (ASA) (Acetylsalicylic Acid (ASA) 81 mg Tablet)	iarasvdpaj(wkosvzjowt) = avjwahnudh ebxifilwfi (ghhbvcyhyr, nherpionoi - mbpuayvltd) View more
NCT00153062 (PRoFESS, CTgov)	Phase 4	Stroke	20,332	Dipyridamole+Aspirin (Aspirin + Extended Release Dipyridamole)	modrtpifng(zzfkbhlkie) = jifojbdhpj mkykkbueun (ppwnmsvnfy, cxeklryzlg - zfkniqczme) View more	-	02 Sep 2009
				Clopidogrel (Clopidogrel)	modrtpifng(zzfkbhlkie) = ojdyhnxdet mkykkbueun (ppwnmsvnfy, bmzmhmqbac - wdcoihpouj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis